Managed Healthcare Executive9d
FDA Approves Subcutaneous Tecentriq to Treat Multiple Cancers
Tecentriq Hybreza will be available in a few weeks and be priced at parity with the IV Tecentriq 1200 mg vial. The FDA has approved Genentech’s Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), ...
Targeted Oncology6d
Atezolizumab After Vemurafenib and Cobimetinib Shows Trend Toward Better OS in Melanoma
Atezolizumab following vemurafenib and cobimetinib shows improved overall survival in BRAF V600–positive melanoma, but not ...
FiercePharma8d
After delay, Roche's Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug
It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s ...
Cure Today9d
FDA Approves Subcutaneous Tecentriq Formulation
Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin ...
Business Wire9d
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
Yahoo Finance8d
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab). The SC formulation was approved under the brand ...
Seeking Alpha8d
Roche wins FDA nod for Tecentriq version developed with Halozyme
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) has received the U.S. FDA’s approval for a subcutaneous version of its cancer immunotherapy, Tecentriq, developed using Halozyme Therapeutics’ (NASDAQ ...
Yahoo Finance9d
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
– Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq – – New ...
Monthly Prescribing Reference8d
FDA Approves Tecentriq Hybreza, a Subcutaneously Administered PD-L1 Inhibitor
The Food and Drug Administration (FDA) has approved Tecentriq Hybreza ™ (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, for all the approved adult indications of intravenous ...